COMMUNIQUÉS West-GlobeNewswire

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
20/02/2026
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
20/02/2026
Enables Potential Shorter Time to Accelerated Approval of PDS0101 in HPV16-positive Head and Neck Cancer PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or [...]
Nasus Pharma to Participate in Upcoming Investor Conferences
20/02/2026
TEL AVIV, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today [...]
Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
20/02/2026
ACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement [...]
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
20/02/2026
DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Biocomposites to launch SYNICEM™ bone cement in UK to ease supply crisis
20/02/2026
Biocomposites responds to NHS supply crisis by bringing forward launch of its SYNICEM™ bone cement products in the UK Over 500,000 SYNICEM™ bone cement packs are already used by surgeons globally every year to help [...]
PL BioScience Signs Exclusive Japanese Distribution Agreement with Summit Pharmaceuticals International
20/02/2026
Summit Pharmaceuticals International Corp. to serve as exclusive distributor for cell culture supplements in Japanese Market. The agreement marks PL BioScience’s first exclusive distribution partnership in Japan. Cell [...]
YWECARE Expands Across Australia as Demand Grows for Transparent and Accountable NDIS Providers
20/02/2026
YWECARE Emerges as One of Australia’s Fast-Growing NDIS Providers Sydney, NSW, Feb. 20, 2026 (GLOBE NEWSWIRE) -- In an industry often under supervision for inconsistency and compliance failures, an NDIS PROVIDER is [...]
Annual report 2025: ALK delivers 15% revenue growth and 26% EBIT margin
20/02/2026
ALK’s (ALKB:DC / Nasdaq Copenhagen: ALK B) full-year results came in at the top end of the latest outlook, supported by solid performance in Q4 and continued commercial momentum. ALK expects sustained high organic [...]
RAMSAY SANTE : New step for Ramsay Santé in connection with Ramsay Health Care's proposal to distribute its shareholding in Ramsay Santé to its shareholders
20/02/2026
PRESS RELEASE Paris, 20 February 2026 New step for Ramsay Santé in connection with Ramsay Health Care's proposal to distribute its shareholding in Ramsay Santé to its shareholders Ramsay Générale de Santé (“ Ramsay [...]
RAMSAY SANTE : Nouvelle étape pour Ramsay Santé, dans le cadre du projet de distribution par Ramsay Health Care à ses actionnaires de sa participation dans Ramsay Santé
20/02/2026
COMMUNIQUÉ DE PRESSE Paris, le 20 février 2026 Nouvelle étape pour Ramsay Santé, dans le cadre du projet de distribution par Ramsay Health Care à ses actionnaires de sa participation dans Ramsay Santé Ramsay Générale de [...]
FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer
20/02/2026
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1 -mutated populations, respectively, versus standard-of-care [...]
Henriette Mersebach to step down as ALK’s head of R&D
20/02/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Henriette Mersebach will step down as Executive Vice President, Research and Development, and as a member of the Board of Management, effective 23 February [...]
O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
20/02/2026
Data from the first in human study on O3R-5671’s potent TNFα inhibition Studies in ulcerative colitis and psoriasis to initiate in H2 2026 Leuven, Belgium. February 20, 2025 . Onco3R Therapeutics, a clinical-stage [...]
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
20/02/2026
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December 31, 2025. FY 2025 [...]
UPDATE – AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results
20/02/2026
Quarterly revenue of $748 million ; GAAP loss of ($0.20) /share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent [...]
Candel Therapeutics Announces Pricing of Public Offering
20/02/2026
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
19/02/2026
SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
STRATA Skin Sciences Confirms Nasdaq Delisting
19/02/2026
HORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]

Pages